Catching the quiet decline: A practical approach to renal disease detection
19 Nov 2026
Zoetis Learning Academy
You’ve run the kidney panel—but is it telling the whole story? As CKD biomarkers multiply, so does confusion about what actually changes clinical decisions. This session clarifies the real-world value and limits of current CKD biomarkers alongside point-of-care urinalysis in dogs and cats. Learn how to integrate serum and urine findings for IRIS staging and monitoring, and leave with a practical framework for choosing the right tests for the right patient—starting with urinalysis on day one.
- Describe the clinical roles and limitations of current CKD biomarkers and point-of-care urinalysis in staging kidney disease in dogs and cats.
- Integrate in-house urinalysis results with serum biomarker data to build a more complete clinical picture of CKD in dogs and cats.
- Differentiate between CKD biomarkers based on clinical value, selecting the most appropriate tests for monitoring disease progression.
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
)
)
)
){kind=logo}
){kind=logo}
